Recent Articles
Three Brain Injuries, One Iboga Protocol, and What It Tells Us
Three people with lasting symptoms after a brain injury went through a six-week iboga microdosing protocol paired with therapy. Two improved and held those gains. One relapsed. A new case series in Frontiers in Pharmacology is going to circulate widely—here’s what it can and can’t tell us, why the dose question matters, and where the sourcing gets uncomfortable.
By Joe Moore
The War on Drugs Was Never About Drugs. Psychedelic Healing Must Reckon With That.
By Sia Henry, J.D.
Filter
Music in Psychedelic-Assisted Therapy: An Introduction to Sound, Playlist Curation, and Why Every Practitioner Needs to Understand Both
If you’ve ever sat with a client in a ketamine or psilocybin session and quietly…
By Kyle Buller, MS
The War on Drugs Is a War On Mothers and Their Children
Betty Aldworth argues that the drug war has functioned as gender policy, separating mothers from…
By Betty Aldworth
No Promises and No Goals
In this excerpt from Radical Adventure, Andrew Feldmár challenges the medicalization of psychedelic psychotherapy and…
By Andrew Feldmár
Why Ketamine Is Changing Psychiatry
Scott Shannon, MD argues that ketamine is doing more than relieving depression. It may be…
By Scott Shannon, MD – Wholeness Center, Fort Collins, Colorado
Whitehouse Directs FDA, HHS and VA to Expand Psychedelic Research Pathways
The White House moved to accelerate federal handling of psychedelic drugs, including ibogaine, while leaving…
By Joe Moore
Op-Ed: Iboga, Ibogaine & 5-MeO-DMT: What gets missed when complex medicines are reduced to standard protocols
What gets lost when iboga is reduced to ibogaine, and complex care is reduced to…